SEC Form 4 · accession 0001193125-26-335007
FATE THERAPEUTICS INC · FATE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Bahram Valamehr
Officer — President and CEO · Director
Period of report
Aug 4, 2026
Accepted (ET)
Aug 5, 2026 · 4:01 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001434316
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Aug 4, 2026 | S | 43,947 | $2.4598 | D | 591,815 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Required number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 75,000 shares of Common Stock underlying RSUs granted to the Reporting Person on July 29, 2024. These sales were automatically executed pursuant to an irrevocable election by the Reporting Person to satisfy tax withholding obligations through "sell-to-cover" transactions and were not made at the discretion of the Reporting Person.
- F2Represents the weighted average sale price of the shares sold ranging from $2.415 to $2.540 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth in this footnote.